Compare · CMMB vs LLY
CMMB vs LLY
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 83698.3x CMMB ($12.7M).
- Over the past year, CMMB is down 65.2% and LLY is up 49.9% - LLY leads by 115.0 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 3 for CMMB).
- LLY has more recent analyst coverage (25 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Eli Lilly and Company
- Price
- $1.77-3.28%
- $1159.49+2.36%
- Market cap
- $12.7M
- $1.07T
- 1M return
- -1.39%
- +18.85%
- 1Y return
- -65.16%
- +49.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 3
- 16
- Recent ratings
- 5
- 25
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CMMB
- SEC Form 3 filed by new insider Melincoff Gwen A
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Mor George Adi
- SEC Form 3 filed by new insider Darvish Nissim
- SEC Form 3 filed by new insider Cohen Neil Harris
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial